Thelansis’s "Chronic Hepatitis B Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Hepatitis B treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Chronic Hepatitis B (CHB) infection is characterized by the presence of Hepatitis B surface antigen (HBsAg) in the serum for at least six months. Following an acute HBV infection, the risk of developing chronicity varies significantly with age — approximately 90% of infected infants progress to chronic infection, compared to less than 5% of adults — and children infected at five years of age or under carry a substantially elevated risk of long-term complications including chronic hepatitis and cirrhosis. HBsAg indicates the presence of hepatitis B viral infection, while HBV DNA quantification, as determined by polymerase chain reaction (PCR) assays, serves as the most direct and reliable measure of viral replication and infectivity, with HBeAg functioning as an additional surrogate marker. In a subset of patients, HBV DNA is detectable in the absence of HBeAg, a phenomenon driven by pre-core and core promoter mutations that impair production and release of the e antigen despite ongoing viral replication, and is associated with progressive liver disease. Severe long-term complications of chronic infection encompass cirrhosis, liver failure, hepatocellular carcinoma (HCC), and mortality, collectively contributing to the substantial global disease burden of CHB.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Chronic Hepatitis B – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 report
Our team will get in touch with you shortly about the Chronic Hepatitis B – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 report.